StockNews.AI
MLTX
StockNews.AI
1 min

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of MoonLake Immunotherapeutics - MLTX

1. Pomerantz LLP investigates MoonLake for potential securities fraud. 2. MoonLake's Phase 3 trial results were disappointing, failing primary endpoints. 3. Stock price plummeted by nearly 90% following trial results announcement. 4. Investors are encouraged to join the class action investigation. 5. Pomerantz is known for significant victories in corporate litigation.

4m saved
Insight
Article

FAQ

Why Very Bearish?

The stock suffered an 89.93% drop, a significant financial loss for investors.

How important is it?

The news directly involves litigation against MoonLake, impacting investor perception significantly.

Why Short Term?

Immediate adverse market reaction to trial outcomes could persist in near future.

Related Companies

AMGNPFEJNJ
, /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of  MoonLake Immunotherapeutics ("Moonlake" or the "Company") (NASDAQ: MLTX). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980. The investigation concerns whether Moonlake and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.  [Click here for information about joining the class action] On September 28, 2025, MoonLake reported disappointing results from its Phase 3 VELA trials evaluating the efficacy and safety of sonelokimab.  One trial failed to meet its primary endpoint, while the other showed only modest gains versus placebo.  Following this news, MoonLake's stock price fell $55.75 per share, or 89.93%, to close at $6.24 per share on September 29, 2025. Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com. Attorney advertising. Prior results do not guarantee similar outcomes.   CONTACT:Danielle PeytonPomerantz LLP[email protected]646-581-9980 ext. 7980 SOURCE Pomerantz LLP WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In

Related News